{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals Hits Day Low at $4.86 Amid Price Pressure
Recursion Pharmaceuticals, Inc. has faced a notable decline in its stock performance, with significant losses over various timeframes. The company reports a challenging financial situation, including a substantial net loss and negative return on equity, raising concerns about its market position within the pharmaceuticals and biotechnology sector.
Recursion Pharmaceuticals, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Recursion Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The stock has experienced fluctuations in price, with notable performance against the S&P 500 over the past week and month, although longer-term returns have faced challenges. Technical indicators present mixed signals regarding market sentiment.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Recursion Pharmaceuticals, Inc. shows a neutral technical trend with mixed indicators, including mildly bullish weekly and monthly MACD, but bearish daily moving averages, suggesting a cautious approach despite recent outperformance against the S&P 500.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Recursion Pharmaceuticals, Inc. shows a neutral technical trend with mixed signals, being mildly bullish on MACD and OBV, while underperforming year-to-date compared to the S&P 500.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Recursion Pharmaceuticals, Inc. shows a neutral technical trend with mixed signals, including mildly bullish weekly and monthly MACD, but a mildly bearish daily moving average, and while it has outperformed the S&P 500 recently, it has underperformed year-to-date, suggesting a cautious approach.
Recursion Pharmaceuticals Hits Day High with 15.28% Surge in Stock Price
Recursion Pharmaceuticals, Inc. has seen a notable stock increase today, contrasting with a slight decline in the S&P 500. Despite recent gains, the company has struggled financially, reporting significant losses over the past year and negative results in its last two quarters, highlighting ongoing challenges in its operations.
Recursion Pharmaceuticals Hits Day High with 16.44% Surge in Stock Price
Recursion Pharmaceuticals, Inc. saw a notable stock price increase on October 8, 2025, amid a declining S&P 500. Despite recent gains, the company has struggled with long-term performance and reported significant financial losses in the first half of the year, raising concerns about its market position.
Recursion Pharmaceuticals Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Recursion Pharmaceuticals, Inc. has recently revised its evaluation amid market fluctuations, with its stock priced at $5.53. The company has experienced significant volatility over the past year, with a notable return of 12.63% over the past week, contrasting with a year-to-date decline of 18.20%.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Recursion Pharmaceuticals, Inc. shows a mildly bearish overall trend despite recent outperformance against the S&P 500, with mixed technical indicators reflecting a shift from bearish to mildly bearish sentiment.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Recursion Pharmaceuticals, Inc. shows a mildly bearish trend with daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, despite significant underperformance over three years compared to the S&P 500.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Recursion Pharmaceuticals, Inc. shows a mildly bearish trend with mixed indicators, having outperformed the S&P 500 recently but significantly underperformed over the long term.
Recursion Pharmaceuticals, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
Recursion Pharmaceuticals, Inc. has experienced significant volatility over the past year, with a stock price currently at $4.91. Technical indicators present a mixed outlook, reflecting challenges in performance compared to the S&P 500. The company faces strategic hurdles in the competitive biotechnology sector.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of August 29, 2025, Recursion Pharmaceuticals, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and weekly MACD, and has significantly underperformed the S&P 500 with a year-to-date return of -27.07% compared to the S&P's 12.22%.
Is Recursion Pharmaceuticals, Inc. overvalued or undervalued?
As of May 12, 2021, Recursion Pharmaceuticals, Inc. is considered risky and overvalued due to poor financial ratios and significant negative returns, underperforming both its peers and the S&P 500.
Is Recursion Pharmaceuticals, Inc. overvalued or undervalued?
As of May 12, 2021, Recursion Pharmaceuticals, Inc. is considered risky and overvalued due to high Price to Book and EV to Sales ratios, a negative P/E ratio, and poor stock performance compared to peers and the S&P 500.
Is Recursion Pharmaceuticals, Inc. technically bullish or bearish?
As of June 18, 2025, Recursion Pharmaceuticals, Inc. shows a mildly bearish trend, with mixed signals from indicators like MACD, Bollinger Bands, and moving averages, suggesting weak bearish sentiment in the market.
What does Recursion Pharmaceuticals, Inc. do?
Recursion Pharmaceuticals, Inc. is a small-cap biotechnology company focused on pharmaceuticals, with recent net sales of $15 million and a net loss of $202 million as of March 2025. The company has a market cap of approximately $1.97 billion and does not pay dividends.
How big is Recursion Pharmaceuticals, Inc.?
As of Jun 18, Recursion Pharmaceuticals, Inc. has a market capitalization of 1,967.44 million, with net sales of 59.79 million and a net profit of -574.78 million over the last four quarters. The company reported shareholder's funds of 1,034.78 million and total assets of 1,448.60 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
